Cargando…

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

PTEN (Phosphatase and tensin homolog) is a tumour suppressor gene commonly defective in human cancer, and is thus a potentially important therapeutic target. Targeting tumour suppressor loss-of-function is possible by exploiting the genetic concept of synthetic lethality (SL). By combining the use o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendes-Pereira, Ana M., Lord, Christopher J., Ashworth, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483146/ https://www.ncbi.nlm.nih.gov/pubmed/23144700 http://dx.doi.org/10.1371/journal.pone.0047249

Ejemplares similares

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
por: Mendes-Pereira, Ana M, et al.
Publicado: (2009)

NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
por: Suwei, Dong, et al.
Publicado: (2015)

The expression of NLK is functionally associated with colorectal cancers (CRC)
por: Chen, Xinyan, et al.
Publicado: (2021)

Erratum to: NLK functions to maintain proliferation and stemness of NSCLC and is a target of metformin
por: Suwei, Dong, et al.
Publicado: (2016)

Dysregulated TRK Signalling is a Therapeutic Target in CYLD Defective Tumours
por: Rajan, Neil, et al.
Publicado: (2011)

NLK-mediated phosphorylation of HDAC1 negatively regulates Wnt signaling
por: Masoumi, Katarzyna Chmielarska, et al.
Publicado: (2017)

Nemo-Like Kinase (NLK) Is a Pathological Signaling Effector in the Mouse Heart
por: Liu, Ruijie, et al.
Publicado: (2016)

Lentivirus-mediated knockdown of NLK inhibits small-cell lung cancer growth and metastasis
por: Lv, Mutian, et al.
Publicado: (2016)

NLK phosphorylates Raptor to mediate stress-induced mTORC1 inhibition
por: Yuan, Hai-Xin, et al.
Publicado: (2015)

NLK interacts with 14-3-3ζ to restore the expression of E-cadherin
por: Chen, Jie, et al.
Publicado: (2020)

In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma
por: Sa, Jason K., et al.
Publicado: (2015)

Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition
por: Sourisseau, Tony, et al.
Publicado: (2010)

The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
por: Turnham, Daniel J., et al.
Publicado: (2020)

Phosphorylation of MAVS/VISA by Nemo-like kinase (NLK) for degradation regulates the antiviral innate immune response
por: Li, Shang-Ze, et al.
Publicado: (2019)

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1
por: Martin, Sarah A., et al.
Publicado: (2010)

Sishen Wan(®) Ameliorated Trinitrobenzene-Sulfonic-Acid-Induced Chronic Colitis via NEMO/NLK Signaling Pathway
por: Wang, Hai-Yan, et al.
Publicado: (2019)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress
por: Hewish, M, et al.
Publicado: (2013)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)

ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation
por: Hanna, Conor, et al.
Publicado: (2020)

Opposing Activities of LIT-1/NLK and DAF-6/Patched-Related Direct Sensory Compartment Morphogenesis in C. elegans
por: Oikonomou, Grigorios, et al.
Publicado: (2011)

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2018)

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence
por: Rovillain, Emilie, et al.
Publicado: (2011)

NLK is required for Ras/ERK/SRF/ELK signaling to tune skeletal muscle development by phosphorylating SRF and antagonizing the SRF/MKL pathway
por: Li, Shang-Ze, et al.
Publicado: (2022)

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2
por: Martin, Sarah A, et al.
Publicado: (2009)

A novel germline mutation of PTEN associated with brain tumours of multiple lineages
por: Staal, F J T, et al.
Publicado: (2002)

Hsa_circ_0009092/miR-665/NLK signaling axis suppresses colorectal cancer progression via recruiting TAMs in the tumor microenvironment
por: Song, Jialin, et al.
Publicado: (2023)

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
por: Punnoose, Elizabeth A, et al.
Publicado: (2015)

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer
por: Chong, Irene Yushing, et al.
Publicado: (2018)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

Biology-driven cancer drug development: back to the future
por: Lord, Christopher J, et al.
Publicado: (2010)

Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer
por: Sun, Lichao, et al.
Publicado: (2016)

PTEN: An Emerging Potential Target for Therapeutic Intervention in Respiratory Diseases
por: Cai, Bangrong, et al.
Publicado: (2022)

Early-onset renal cell carcinoma in PTEN harmatoma tumour syndrome
por: Kim, Raymond H., et al.
Publicado: (2020)

Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas
por: Seeling, Carolin, et al.
Publicado: (2023)

Tumours and tremors: how PTEN regulation underlies both
por: Kim, R H, et al.
Publicado: (2006)

Lentivirus-based RNA Silencing of Nemo-like Kinase (NLK) Inhibits the CAL 27 Human Adenosquamos Carcinoma Cells Proliferation and Blocks G0/G1 Phase to S Phase
por: Zhang, Bin, et al.
Publicado: (2013)

Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
por: Fu, Caiyun
Publicado: (2020)

Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency.
por: Chen, Chien-Ju, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mbg8ro7s9nbo0e0p3pomli0d99